Dravet syndrome was described in 1978 by Dravet (1978) under the name of severe
myoclonic epilepsy in infancy (SMEI). The characteristics of the syndrome were confirmed …

Cognitive and behavioural comorbidities are often seen in children with epilepsy, and are
more common and severe in refractory epilepsy. These comorbidities are associated with …

Objectives To establish standards for early, cost-effective, and accurate diagnosis; optimal
therapies for seizures; and recommendations for evaluation and management of …

OBJECTIVE: De novo mutations of the gene sodium channel 1α (SCN1A) are the major
cause of Dravet syndrome, an infantile epileptic encephalopathy. US incidence of DS has …

Dravet syndrome is a severe infantile onset epileptic encephalopathy associated with
mutations in the sodium channel alpha 1 subunit gene SCN1A. To date no large studies …

Aim To test the hypothesis that higher seizure burden in Dravet syndrome is associated with
increased comorbidities and lower quality of life (QoL) in a large cohort of patients with …

Aim To assess the prevalence and risk factors for autism spectrum disorder (ASD) in
epilepsy, and to better understand the relationship and comorbidity between these …

Dravet syndrome (DS) is a severe, rare, and complex developmental and epileptic
encephalopathy affecting 1 in 16 000 live births and characterized by a drug‐resistant …

Impairments in cognition are common in epilepsy and may be caused or exacerbated by
antiseizure medications (ASMs). Positive effects on cognition may also be seen with some …

Severe myoclonic epilepsy of infancy (SMEI) is a complex form of epilepsy that was first
described in France in 1978. Because the myoclonic component of this epilepsy is not …